Related Experiment Videos
[Pathophysiology and current therapy of congestive heart failure due to idiopathic cardiomyopathy]
1Department of Internal Medicine, Faculty of Medicine, Kyoto University.
Insights
Congestive heart failure (CHF) management differs for dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). ACE inhibitors and beta-blockade are key for DCM, while verapamil and beta-blockade aid HCM patients.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Idiopathic cardiomyopathies are a significant cause of congestive heart failure (CHF).
- Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) present distinct pathophysiological mechanisms leading to CHF.
Purpose:
- To review the current understanding and management strategies for congestive heart failure (CHF) arising from idiopathic cardiomyopathies, specifically DCM and HCM.
- To highlight the pharmacological approaches and their efficacy in improving patient outcomes.
Summary:
- Congestive heart failure in DCM is primarily due to myocardial systolic dysfunction. First-line treatments include diuretics, angiotensin-converting enzyme (ACE) inhibitors, and digitalis, with ACE inhibitors proven to prolong life and enhance quality of life. Long-term beta-blockade therapy has also demonstrated significant benefits.
- In contrast, CHF in HCM results from decreased myocardial compliance. Verapamil improves relaxation and diastolic filling, and alleviates myocardial ischemia. Beta-blockade is beneficial by reducing the pressure gradient and myocardial oxygen consumption.
- Idiopathic restrictive cardiomyopathy, though rare, also causes CHF due to decreased myocardial compliance.
Impact:
- This review provides a concise overview of therapeutic options for managing CHF in different idiopathic cardiomyopathy subtypes.
- Understanding these distinctions is crucial for optimizing treatment strategies and improving prognosis for patients with these complex cardiac conditions.
Abstract:
Congestive heart failure (CHF) due to idiopathic cardiomyopathy is reviewed. CHF in dilated cardiomyopathy (DCM) is caused mainly by myocardial systolic dysfunction. Diuretics, angiotensin-converting enzyme (ACE) inhibitors and digitalis are the first choice drugs. ACE inhibitors have been shown to be effective in prolonging life and improving quality of life. Recently, long-term beta-blockade therapy has been shown to be useful. CHF in hypertrophic cardiomyopathy (HCM) is caused by decreased myocardial compliance. The beneficial effect of verapamil in HCM is related to improved relaxation and diastolic filing. Verapamil is also effective in relieving myocardial ischemia. Beta-blockade decreases pressure gradient and oxygen consumption. Idiopathic restrictive cardiomyopathy is a very rare disease and decreased myocardial compliance is responsible for CHF.